Enanta Pharmaceuticals, Inc.

ENTA

US29251M1062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
12.37 ^USD	-0.88%		-7.13%	+31.46%

Feb. 09	Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	MT
Feb. 07	Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P Biotechnology Select Industry Index

September 18, 2023 at 12:00 am EDT

Latest news about Enanta Pharmaceuticals, Inc.

Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	Feb. 09	MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M	Feb. 07	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024	Dec. 26	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Nov. 24	MT
Sector Update: Health Care	Nov. 24	MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf	Nov. 24	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating	Nov. 22	MT
HC Wainwright Cuts Enanta Pharmaceuticals' Price Target to $28 From $30, Maintains Buy Rating	Nov. 21	MT
Transcript : Enanta Pharmaceuticals, Inc., Q4 2023 Earnings Call, Nov 20, 2023	Nov. 20
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q4 Revenue $18.9M, vs. Street Est of $17.5M	Nov. 20	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 20	CI
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Nov. 20	CI
HC Wainwright Adjusts Enanta Pharmaceuticals Price Target to $30 From $48, Maintains Buy Rating	23-10-23	MT
Transcript : Enanta Pharmaceuticals, Inc. - Special Call	23-10-20
Enanta Pharmaceuticals Receives Speculative Risk Qualifier on Sector Perform Rating From RBC, Price Target Cut to $15 From $25	23-10-02	MT
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P Biotechnology Select Industry Index	23-09-18	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P 600	23-09-18	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P Composite 1500	23-09-18	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P 600 Health Care	23-09-18	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from S&P 1000	23-09-18	CI
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $25 From $30, Maintains Perform Rating	23-08-09	MT

Chart Enanta Pharmaceuticals, Inc.

Duration

Period

More charts

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

Sector

Biotechnology & Medical Research

Calendar

06:00am - ESCMID Global Conference - Abstract Number: 02980

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Enanta Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

12.37 USD

Average target price

20.88 USD

Spread / Average Target

+68.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENANTA PHARMACEUTICALS, INC.	+31.46%	262M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research